Guangdong, China

Main Item: Peptide
Business Type: Manufacturer

Retatrutide is the newest GLP-1R agonist and was approved by the FDA as a once-weekly injection for the treatment of T2DM in late 2017. The peptide is chemically similar to semaglutide,tirzepatide, with the inclusion of two structural modifications...

Send your message to this supplier
Belle Liu ( Shenzhen Ruiqixin Technology Co.,Ltd )
(20~4000 Characters)
Listed on Jun 5, 2024